Education
About Us
Working with TipRanks
Follow Us
Kontafarma China Holdings Ltd (HK:1312)
:1312
1312 Stock Chart & Stats
HK$0.03
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.03
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.02 - HK$0.05
Previous CloseN/A
Volume162.00K
Average Volume (3M)9.95M
Market Cap
HK$172.94M
Enterprise ValueHK$330.47M
Total Cash (Recent Filing)HK$78.33M
Total Debt (Recent Filing)HK$235.86M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding5,588,572,000
10 Day Avg. Volume1,701,000
30 Day Avg. Volume9,954,100
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.15
Price to Sales (P/S)0.16
P/FCF Ratio4.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market DemandThe increasing demand for healthcare products in China provides a strong market opportunity for Kontafarma, supporting potential long-term revenue growth.
Business Model DiversificationA diversified revenue model with multiple streams, including prescription and OTC products, helps mitigate risks and stabilize income, enhancing business resilience.
Strategic PartnershipsStrategic partnerships for R&D can drive innovation and product development, potentially leading to new revenue streams and competitive advantages.
Bears Say
Profitability IssuesPersistent profitability challenges and declining revenues indicate difficulties in maintaining market share and pricing power, affecting long-term sustainability.
Weak Cash FlowInconsistent cash flow generation limits the company's ability to fund operations and growth internally, posing risks to financial stability and expansion plans.
Declining EquityContinuous losses leading to declining equity weaken the financial position, reducing the company's ability to leverage financing for growth and operations.
Kontafarma China Holdings Ltd News
1312 FAQ
What was Kontafarma China Holdings Ltd’s price range in the past 12 months?
Kontafarma China Holdings Ltd lowest stock price was HK$0.02 and its highest was HK$0.05 in the past 12 months.
What is Kontafarma China Holdings Ltd’s market cap?
Kontafarma China Holdings Ltd’s market cap is HK$172.94M.
When is Kontafarma China Holdings Ltd’s upcoming earnings report date?
Kontafarma China Holdings Ltd’s upcoming earnings report date is Mar 26, 2026 which is in 31 days.
How were Kontafarma China Holdings Ltd’s earnings last quarter?
Kontafarma China Holdings Ltd released its earnings results on Aug 28, 2025. The company reported -HK$0.051 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.051.
Is Kontafarma China Holdings Ltd overvalued?
According to Wall Street analysts Kontafarma China Holdings Ltd’s price is currently Overvalued.
Does Kontafarma China Holdings Ltd pay dividends?
Kontafarma China Holdings Ltd pays a Annually dividend of HK$0.004 which represents an annual dividend yield of N/A. See more information on Kontafarma China Holdings Ltd dividends here
What is Kontafarma China Holdings Ltd’s EPS estimate?
Kontafarma China Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kontafarma China Holdings Ltd have?
Kontafarma China Holdings Ltd has 5,588,572,000 shares outstanding.
What happened to Kontafarma China Holdings Ltd’s price movement after its last earnings report?
Kontafarma China Holdings Ltd reported an EPS of -HK$0.051 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kontafarma China Holdings Ltd?
Currently, no hedge funds are holding shares in HK:1312
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kontafarma China Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.28%
12-Months-Change
Fundamentals
Return on Equity
-41.48%
Trailing 12-Months
Asset Growth
-31.85%
Trailing 12-Months
Company Description
Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd. engages in the manufacture and sale of cement. It operates through the following segments: Pharmaceutical and Fitness Business. The Pharmaceutical Business segment involves in manufacture and sales of prescription drugs and laboratory related products. The Fitness Business segment includes the operation of fitness centers and provide consultation services for fitness and health activities and operate the franchise business for royalty fee income. The company was founded on March 21, 2011 and is headquartered in Hong Kong.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
China NT Pharma Group Co., Ltd.
―
PuraPharm Corp. Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Huakang Biomedical Holdings Company Limited
―